PrEP

Investigators find that only 48% of surveyed health care providers had ever prescribed PrEP.

Colleen Kelley, MD, the biggest barriers to HIV prevention methods and how to overcome them.

A new study reports that PrEP users were more likely to receive more primary health care services compared with non-PrEP users.

Stay up-to-date on the latest infectious disease news by reading the top 5 articles of the week.

Text messaging is an easy way to improve medication adherence rates, but success depends on a number of factors including youth and race.

A recent study finds that shortening the rabies pre-exposure prophylaxis regimen is both effective and safe.

In case you missed them, we've compiled the top 5 articles from this past week.

Douglas Krakower, MD, discusses the challenges of predicting HIV acquisition in large populations using electronic health records.

In case you missed them, we've compiled the top 5 articles from this past week.

Implants are promising for long-term, sustained, and reversible delivery of ARV drugs that may bypass adherence challenges for end users.

Douglas Krakower, MD, discusses which variables in electronic health records could be used to identify candidates for pre-exposure prophylaxis.

Colleen Kelley, MD, describes the role of health care providers in linking patients with PrEP.

Hair levels are found to be the strongest independent predictor of virologic success in a recent treatment trial.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

At CROI 2018, Dr. Linda-Gail Bekker highlighted 7 controversies surrounding PrEP and provided conference attendees with enough evidence to separate fact from fiction.

One study takes a look at how out-of-pocket costs impede the use of pre-exposure prophylaxis in young men who have sex with men.

Better understanding of the vaginal microbiome may provide new insights into HIV acquisition.

First detailed analysis by race and risk group finds that two-thirds of those who could benefit from PrEP are African American or Latino, but they account for the smallest percentage of prescriptions to date.

Research suggests misperceptions about the risk of HIV infection should be corrected at the time of testing, with PrEP initiated same-day if appropriate.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

PrEP does not have to be taken daily to be effective, but consistency and a strong support system are key.

A new study from investigators at Drexel University revealed that if 25% of high-risk men who have sex with men appropriately used the pre-exposure prophylaxis (PrEP), 3 out of every 10 HIV infections in this population could be prevented.

The National Institutes of Health (NIH) have announced plans for a new trial testing the effectiveness of the injectable pre-exposure prophylaxis (PrEP) drug, cabotegravir, in sexually-active women.

Although a once-daily pill to prevent HIV exists, US populations at highest risk have the lowest rates of usage.

NIAID director Dr. Anthony S. Fauci stresses in a recent commentary that, from a practical standpoint, the development of a moderately effective HIV vaccine is “essential” to ending the pandemic.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

A Phase 2 study showed that maraviroc-containing antiretroviral regimens were generally safe and well-tolerated in a female population.

Alex Rinehart, PhD, explains if cabotegravir interacts with any other medications.

A NIH network study finds that pre-exposure prophylaxis, approved for daily use in adults, can also reduce chances of HIV infection in young male adolescents.

Alex Rinehart, PhD, identifies the target population for cabotegravir.